The speed with which TG Therapeutics burst on the scene, along with the impressive potency and safety of its novel combinations of cancer drugs, has perhaps blinded observers to the unique business model that has carried it this far.
Cancer specialist TG Therapeutics Inc. has recently shown positive mid-stage data for its assets, both alone and in combination, in patients with advanced B-cell cancers. The speed with which it burst on the scene, combined with the potency and safety of its drugs, has perhaps blinded observers to the unique business model that has carried it this far.
The main element in the model is TG’s dedication from the start to proprietary combinations of its own drugs. TG...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
